GovernmentAI-TechBusinessScienceSportsEntertainmentGeneral
AI-Tech

Autonomous robots begin drawing blood in outpatient clinics

Regulatory clearance for an automated phlebotomy system shifts routine venipuncture to machines, but human oversight remains essential for complex cases.

By Primary News Team

Autonomous robots begin drawing blood in outpatient clinics
A woman uses the Vitestro Aletta robotic device for an automated blood draw. Source: Vitestro
Published8 Sep 2026, 14:06 Last updated8 Sep 2026, 14:06 Sources
Show reference links Marks each sentence drawn from a source or a contributor

Drawing venous blood remains the single most common invasive procedure in modern medicine.12 Every diagnostic blood test relies on a healthcare worker locating a vein beneath the skin, inserting a hollow needle at the correct depth and angle, collecting fragile blood cells without rupturing them, and dressing the puncture site. While clinical laboratories have automated nearly every stage of chemical analysis inside test tubes, the physical act of getting blood out of an arm has changed little over the past century.

That manual bottleneck increasingly collides with staffing shortages across healthcare systems. When phlebotomy clinics run short of trained staff, outpatient diagnostic testing backs up, delaying routine blood counts, cholesterol checks, and metabolic panels.31 A newly authorized robotic platform aims to perform these routine blood draws without direct manual intervention, using a sequence of imaging sensors, artificial intelligence algorithms, and motorized needle positioning to standardize how blood samples are gathered.23

How does a machine find and draw blood from a vein?

A robotic blood draw replaces human touch and visual inspection with a layered series of optical and acoustic sensors that locate and verify target vessels.34 The procedure requires several distinct physical steps to succeed in sequence. First, a mechanical cuff tightens around the upper arm to build venous pressure and make the vessels swell.32 Optical sensors then scan the inner elbow, using near-infrared light to detect hemoglobin beneath the skin and create a preliminary map of surface veins.2 Because optical light cannot measure depth or distinguish between veins and arteries, an ultrasound probe glides across the arm to determine the precise depth and orientation of the chosen vessel.35 Doppler ultrasound, an acoustic method that measures the direction and velocity of fluid movement, assesses blood flow to ensure the needle targets a vein rather than an adjacent artery.32

Autonomous robots begin drawing blood in outpatient clinics
A woman places her arm into an Aletta robotic blood draw machine, which uses sensors to locate target vessels. Source: Vitestro

Once the system confirms a suitable vessel, a sterile needle mechanism guides the puncture with submillimeter precision.56 The machine draws blood into collection tubes, mechanically inverting each tube end-over-end to mix the sample with required chemical additives before retracting the needle and placing an adhesive bandage over the puncture.35 Built-in safety sensors track arm position and automatically disengage the needle if the patient moves abruptly during collection.23

What did the clinical trials find?

The system achieved a 94.5 percent first-attempt success rate among 1,633 adult patients in a prospective multicenter trial published in the journal Clinical Chemistry, measured when the device successfully identified a suitable vein.1 In that trial, conducted across outpatient departments at Dutch hospitals including Amsterdam University Medical Center, St. Antonius Hospital, OLVG Lab, and Result Laboratory, the robot recorded a hemolysis rate of 0.3 percent across the 1,633 enrolled participants, reflecting minimal rupturing of fragile red blood cells during collection.

Performance held steady across groups that frequently present technical challenges for manual venipuncture. The device reached a 97.4 percent first-stick success rate among trial participants with a body mass index above 30, a 93.4 percent rate in patients older than 65 years, and a 92.7 percent rate in patients who self-reported difficult venous access.78 Device-related adverse events occurred in 0.6 percent of the 1,633 patients, and all recorded events were categorized as mild.78 In patient surveys conducted during the trial, 90 percent of participants reported experiencing pain levels less than or comparable to a conventional manual blood draw.75

What are the limits of autonomous phlebotomy?

The published trial results demonstrate how the system performs in routine outpatient settings, but they do not show that machines can handle all clinical venipunctures.41 The device operates under strict candidacy criteria, excluding pediatric patients, individuals under 16 or 22 years depending on regional rules, and patients with severe scarring, burns, amputations, or vascular access complications such as arteriovenous fistulas.45 Furthermore, the 94.5 percent success figure is calculated only from patients in whom the device successfully identified a suitable vein; when the sensors cannot detect an appropriate vessel, the system halts and refers the patient to a human phlebotomist.38

Autonomous robots begin drawing blood in outpatient clinics
A woman interacts with an autonomous robotic blood draw device, designed for routine blood sample collection. Source: Vitestro

Independent researchers have also emphasized that key technical questions require broader validation. Optical near-infrared imaging relies on light contrast that melanin in darker skin tones can absorb, making the skin-agnostic performance of the secondary ultrasound sensor critical to verify across diverse populations.5 Additional measures of specimen integrity, including tube fill accuracy for coagulation studies and sample quality under high-volume laboratory conditions, still await independent evaluation in multi-institution clinical settings.34

What happens next for automated blood draws?

On August 19, 2026, the United States Food and Drug Administration granted De Novo marketing authorization to Vitestro for the Aletta device, establishing a new regulatory classification for standalone robotic phlebotomy systems.9 Under the terms of the authorization, the device is cleared for use in adult outpatient settings under the supervision of a trained phlebotomist, with one supervisor permitted to manage up to three machines concurrently.210

Vitestro, founded in 2017 in Utrecht, Netherlands, previously secured CE marking in Europe in August 2024 and completed a 70 million dollar Series B financing round in March 2026 to support manufacturing and clinical rollout.1112 US clinical investigators, including Brooke Katzman at the Mayo Clinic and Gregory Retzinger at Northwestern University Feinberg School of Medicine, are preparing prospective multicenter validation trials to evaluate routine clinical performance, sample quality, and diagnostic accuracy before widespread commercial deployment across American hospital networks.

This piece was prepared from clinical trial publications, regulatory filings, and public records; the authors have not been interviewed.

References

This article is based on 17 sources, listed in the order they are cited.

  1. 1 NT Nexithon Technologies third party · 19 Aug 2026 A Robot Drew Blood in Denmark. Humans Still Won the Hard Cases. See the source
  2. 2 F FDA FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device See the source
  3. 3 ED Elie Dolgin announcement · 7 Sep 2026 This Robot Will Draw Your Blood Now See the source
  4. 4 P phlebotomy.com Aletta: An Update About Vitestro See the source
  5. 5 V vitestro.com third party · 12 Nov 2025 Aletta for Laboratory specialists - Vitestro See the source
  6. 6 V vitestro.com third party · 28 Nov 2025 FAQ - Vitestro See the source
  7. 7 CL Clinical Lab Products third party · 14 Apr 2026 Autonomous Robotic Phlebotomy Shows High Success Rates in Multicenter Trial See the source
  8. 8 B BioPlayground third party · 21 Aug 2026 Vitestro's Aletta Becomes First FDA-Approved Autonomous Blood Draw Robot via De Novo Pathway See the source
  9. 9 V vitestro.com third party · 20 Aug 2026 Vitestro Receives FDA De Novo Authorization for Aletta See the source
  10. 10 M morningstar.com FDA Gives Marketing Authorization to Vitestro's Robotic Blood Draw Device See the source
  11. 11 N news.bpdata.com third party · 26 Aug 2026 FDA Clears Aletta, First Autonomous Blood‑draw Robot, via De Novo Pathway See the source
  12. 12 V vitestro.com third party · 17 Jun 2025 News - Vitestro See the source
  13. 13 CL Clinical Lab Products third party · 30 Jul 2026 Autonomous Robotic Phlebotomy System Shows 94.5% Success Rate in Multicenter Trial See the source
  14. 14 V vitestro.com third party · 19 Jun 2025 Patients - Vitestro See the source
  15. 15 V vitestro.com third party · 17 Jun 2025 Homepage - Vitestro See the source
  16. 16 V vitestro.com third party · 6 Mar 2025 Vitestro Unveils Aletta®: The World’s First Autonomous Robotic Phlebotomy Device™ (ARPD™) - Vitestro See the source
  17. 17 H hst.org.tw Meet Aletta: The first FDA approved robotic blood draw device | 產業資訊 | 台灣智慧醫療創新整合平台 See the source